Disease
Bladder cancer膀胱癌
ICD-10: C67 — Malignant neoplasm of bladder
Key figures
Published values only. Every tile opens the section that carries its source, its year and its caliber.
Disease details
- Standard Chinese name
- 膀胱癌
- English name
- Malignant neoplasm of bladder
Values written in Chinese are quoted as published by the source.
Also known as
- Bladder carcinoma
- Urothelial carcinoma
Treatment cost ranges
Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.
| Treatment path | Cost range | Price basis | Data year |
|---|---|---|---|
| Surgery 手术 | 67500 – 67500 CNY | Condition package price 病种打包全包价 | 2020 |
| Surgery 手术 | 18000 – 18000 CNY | Condition package price 病种打包全包价 | 2020 |
The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 67500 CNY. Each row keeps its own data year and caliber.
2 cost ranges for this condition, each with its source on the row page.
Values written in Chinese are quoted as published by the source.
Five-year survival
5-year survival rate 71.5%
- Population
- Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
- Period
- 2019–2021
- Publisher
- National Cancer Center 国家癌症中心
- Value nature
- Estimated value (hybrid analysis) 估计值（混合法）
- Registry scope
- 281 population-based cancer registries 281 个肿瘤登记处
- Stage data availability
- Not published
Values written in Chinese are quoted as published by the source.
How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.
Hospitals with a published record for this condition
Selected using official public data sources
These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.
How these hospitals were selected
Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.
Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.
Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.
When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.
The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.
-
Chinese PLA General Hospital中国人民解放军总医院
Fudan specialty reputation ranking 2023
- Urology #1 https://www.fdygs.com/news2023-1.aspx
Also ranked: General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4 in the Fudan list.
-
West China Hospital, Sichuan University四川大学华西医院
Fudan specialty reputation ranking 2023
- Urology #2 (tied) https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Also ranked: General Surgery #3, Thoracic Surgery #4, Otorhinolaryngology #8 in the Fudan list.
-
Peking University First Hospital北京大学第一医院
Fudan specialty reputation ranking 2023
- Urology #2 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.pkufh.com/Html/News/Articles/64494.html
Also ranked: Infectious Diseases 传染感染 #9, General Surgery nominated, Gynecology nominated in the Fudan list.
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院
Fudan specialty reputation ranking 2023
- Urology #4 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.gzsys.org.cn/basic/453
Also ranked: General Surgery nominated, Gynecology nominated, Otorhinolaryngology nominated in the Fudan list.
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院
Fudan specialty reputation ranking 2023
- Urology #5 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.tjh.com.cn/contents/934/27291.html
Also ranked: General Surgery #6, Gynecology #2, Respiratory Medicine #8 in the Fudan list.
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属仁济医院
Fudan specialty reputation ranking 2023
- Urology #6 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.renji.com/gh/article/list/01/01
Also ranked: Gynecology #10, Gastroenterology #1, Nuclear Medicine 核医学 #8 in the Fudan list.
-
Peking Union Medical College Hospital中国医学科学院北京协和医院
Fudan specialty reputation ranking 2023
- Urology #8 https://www.fdygs.com/news2023-1.aspx
Also ranked: General Surgery #1, Gynecology #1, Otorhinolaryngology #4 in the Fudan list.
-
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院
Fudan specialty reputation ranking 2023
- Urology #9 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level A) http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Also ranked: General Surgery #7, Infectious Diseases 传染感染 #2, Thoracic Surgery nominated in the Fudan list.
Clinical trials (investigational treatments)
In addition to standard care, clinical research studies for Bladder cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.
-
Study A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid technologyKYLL-202407-046-1
- Lead investigator
- Chenjun · professor
- Hospital
- The Second Hospital of Shandong University
- Status
- Recruiting
- Registry
- NCT06662071
-
Study A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
- Hospital
- Beijing Friendship Hospital, Capital Medical University
- Status
- Recruiting
- Registry
- NCT06319820
-
Study A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
- Hospital
- Peking University First Hospital
- Status
- Recruiting
- Registry
- NCT06919965
-
Study A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion
- Hospital
- Peking University Cancer Hospital
- Status
- Recruiting
- Registry
- NCT07122414
-
Study An Single-arm, Multicenter Phase I/II Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
- Hospital
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Status
- Recruiting
- Registry
- NCT06378242
14 more registered studies
-
Study A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer
- Hospital
- Peking University First Hospital
- Status
- Recruiting
- Registry
- NCT07283835
-
Study Non-invasive Urinary Genomics-Based Risk Assessment for Early Diagnosis of Urothelial Carcinoma
- Hospital
- Henan Provincial People's Hospital
- Status
- Recruiting
- Registry
- NCT07614594
-
Study Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer: a Prospective, Observational Study
- Lead investigator
- Qiyun Ou · Dr.
- Hospital
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Status
- Recruiting
- Registry
- NCT06775977
-
Study Al18F-HER2-BCH PET/CT to Predict Response in Bladder Cancer Patients Treated With HER2 ADC
- Hospital
- Peking University Cancer Hospital
- Status
- Recruiting
- Registry
- NCT06548529
-
Study A Phase Ib/II Prospective Study to Evaluate the Safety and Efficacy of the Combination of Neoadjuvant Palbociclib and Tislelizumab in Platinum-refractory cT2-4aN0M0 Bladder Urothelial Carcinoma.
- Hospital
- Nanfang Hospital
- Status
- Recruiting
- Registry
- NCT06364956
-
Study Study Protocol for Evaluating the Efficacy of Anti-HER-2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
- Hospital
- Qilu Hospital of Shandong University
- Status
- Recruiting
- Registry
- NCT07379268
-
Study A Multicenter, Randomized Controlled Phase II Study of Evaluating the Efficacy and Safety of Immunotherapy Combined With Oral Probiotics Compound (Biolosion) in Patients With Advanced Urothelial Carcinoma
- Lead investigator
- Shi Yanxia · Professor
- Hospital
- Sun Yat-sen University Cancer Center
- Status
- Recruiting
- Registry
- NCT06904573
-
Study Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial
- Lead investigator
- Dong-Xin Wang · Professor
- Hospital
- Peking University First Hospital
- Status
- Recruiting
- Registry
- NCT04532606
-
Study A Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma
- Hospital
- Second Hospital of Tianjin Medical University
- Status
- Not yet recruiting
- Registry
- NCT07756008
-
Study A Prospective, Multicenter, Single-Arm, Phase Ⅱ, Exploratory Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
- Hospital
- Fujian Medical University Union Hospital
- Status
- Not yet recruiting
- Registry
- NCT06630871
-
Study A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.
- Hospital
- Nanfang Hospital
- Status
- Not yet recruiting
- Registry
- NCT06364904
-
Study Disitamab Vedotin Plus Toripalimab for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
- Lead investigator
- Cheng Fan · Chief Physician, Dept. of Urology
- Hospital
- Renmin Hospital of Wuhan University
- Status
- Not yet recruiting
- Registry
- NCT07151560
-
Study Preliminary Clinical Study Evaluating the Therapeutic Response and Safety of Intravesical Perfusion With Plasma-Activated Saline Solution in Patients With Bladder Cancer
- Lead investigator
- Benkang Shi · Head of Urology Department
- Hospital
- Qilu Hospital of Shandong University
- Status
- Not yet recruiting
- Registry
- NCT07272603
-
Study Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria: a Prospective, Multicenter Cohort Study
- Status
- Not yet recruiting
- Registry
- NCT06469229
This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.
Hospitals with a national key specialty record
Show the hospital records 30 hospitals with a key-specialty record
Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.
30 hospitals with a matching national key specialty record.
Values written in Chinese are quoted as published by the source.
Questions about this condition
We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.
ICD codes
Show the code table 1 ICD code
| Version | Code | Name in that version |
|---|---|---|
| ICD-10-WHO | C67 | Malignant neoplasm of bladder |
Rows are the WHO ICD-10 entries for this condition, quoted as published.
Source & evidence
- Source URL
- https://qzybj.quanzhou.gov.cn/qt/gzcx/bzsfcx/202006/P020221216571645625406.pdf
- Source scheme
- https
- Source type
- Provincial health commission
- Evidence level
- A - said by a provincial health commission or university
- Retrieved on
- 2026-09-30